Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

Autor: John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett

Publikováno v: Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 64 (1), pp.130-139. ⟨10.1080/10428194.2022.2136956⟩

International audience; The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac0ac7789adff53db7242de3311959b0
https://pubmed.ncbi.nlm.nih.gov/36398795

Pulmonary AL amyloidosis: A review and update on treatment options

Autor: Lindsay N. Moy, Mahum Mirza, Blake Moskal, Nahren Asado, Bhaven Shah, Jacob Bitran

Publikováno v: Annals of Medicine & Surgery. 80

Amyloidosis is a rare disease that involves the extracellular deposition of abnormally folded proteins, precipitating organ dysfunction. Pulmonary amyloidosis is frequently characterized by the AL amyloid subtype and can be localized or associated wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89274bb1ce2e05a834f043a8588a9cf7
https://doi.org/10.1016/j.amsu.2022.104060

Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients

Autor: Navroop Gill, Anjana Chandran, Brian Adley, Jacob Bitran

Publikováno v: Cureus

Increased risk for the development of therapy-induced myeloid leukemia following the treatment of breast cancer has typically been associated with the use of regimens containing anthracyclines or alkylating agents. We present two cases of estrogen re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4d40f51c14b6fa55cd2a517e4802dfb
http://europepmc.org/articles/PMC7785496

High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry

Autor: Donald A. Berry, Gloria Broadwater, John P. Klein, Karen Antman, Joseph Aisner, Jacob Bitran, Mary Costanza, Cesar O. Freytes, Edward Stadtmauer, Robert Peter Gale, I. Craig Henderson, Hillard M. Lazarus, Philip L. McCarthy, Larry Norton, Howard Parnes, Andrew Pecora, Michael C. Perry, Philip Rowlings, Gary Spitzer, Mary M. Horowitz

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(3)

PURPOSE: To assess survival of patients with metastatic breast cancer treated with high-dose chemotherapy (HDC) versus standard-dose chemotherapy (SDC). PATIENTS AND METHODS: SDC in four Cancer and Leukemia Group B (CALGB) trials was compared with he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3f24644437422ebf495d4e1a2d2f8c
https://pubmed.ncbi.nlm.nih.gov/11821456

Ascites as the major manifestation of systemic lupus erythematosus

Autor: Jacob Bitran, Dennis McShane, Michael H. Ellman

Publikováno v: Arthritis & Rheumatism. 19:782-785

It is uncommon for ascites secondary to severe peritoneal inflammation to be the major manifestation of systemic lupus erythematosus. Chronic nonspecific inflammation with a granular type immunofluorescent staining along the mesothelial layer of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be7c3d8cd4cafd0e2b22642eada1cb2a
https://doi.org/10.1002/1529-0131(197607/08)19:4<782::aid-art1780190421>3.0.co